IN8bio, Inc. (INAB)
1.09
-0.05
(-4.39%)
USD |
NASDAQ |
Sep 09, 13:38
IN8bio Total Liabilities (Quarterly) : 3.382M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.382M |
| March 31, 2026 | 3.484M |
| December 31, 2025 | 4.724M |
| September 30, 2025 | 3.579M |
| June 30, 2025 | 4.132M |
| March 31, 2025 | 5.992M |
| December 31, 2024 | 7.509M |
| September 30, 2024 | 7.378M |
| June 30, 2024 | 8.875M |
| March 31, 2024 | 8.023M |
| December 31, 2023 | 8.772M |
| Date | Value |
|---|---|
| September 30, 2023 | 8.45M |
| June 30, 2023 | 7.919M |
| March 31, 2023 | 7.89M |
| December 31, 2022 | 10.31M |
| September 30, 2022 | 8.819M |
| June 30, 2022 | 4.42M |
| March 31, 2022 | 3.703M |
| December 31, 2021 | 4.04M |
| September 30, 2021 | 4.096M |
| June 30, 2021 | |
| March 31, 2021 | 4.104M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 21.74M |
| Shareholders Equity (Quarterly) | 18.36M |
| Debt to Equity Ratio | 0.1186 |
| Current Ratio | 8.206 |
| Net Debt Paydown Yield | 3.02% |